vs
Side-by-side financial comparison of IMMUCELL CORP (ICCC) and Anbio Biotechnology (NNNN). Click either name above to swap in a different company.
ImmuCell Corp is a US-based animal health biotechnology company that develops, manufactures and markets innovative products for livestock, primarily dairy cattle. Its core offerings include preventive and therapeutic solutions for common bovine health issues such as mastitis, serving agricultural producers and veterinary providers across North America.
Anbio Biotechnology is a specialized in vitro diagnostic (IVD) biotechnology enterprise that develops, manufactures and markets a wide range of rapid testing solutions. Its product portfolio covers infectious disease detection, cardiovascular marker tests, food safety screening kits and supporting diagnostic tools, serving clinical labs, healthcare facilities and supervision bodies across global markets.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $5.5M | — | ||
| Q2 25 | $6.4M | — | ||
| Q1 25 | $8.1M | — | ||
| Q4 24 | $7.8M | — | ||
| Q3 24 | $6.0M | — | ||
| Q2 24 | $5.5M | — | ||
| Q1 24 | $7.3M | — | ||
| Q4 23 | $5.1M | — |
| Q3 25 | $-139.7K | — | ||
| Q2 25 | $501.9K | — | ||
| Q1 25 | $1.4M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-701.7K | — | ||
| Q2 24 | $-1.5M | — | ||
| Q1 24 | $-437.9K | — | ||
| Q4 23 | — | — |
| Q3 25 | 42.9% | — | ||
| Q2 25 | 43.7% | — | ||
| Q1 25 | 41.6% | — | ||
| Q4 24 | 36.5% | — | ||
| Q3 24 | 26.3% | — | ||
| Q2 24 | 22.5% | — | ||
| Q1 24 | 31.6% | — | ||
| Q4 23 | 24.7% | — |
| Q3 25 | 0.4% | — | ||
| Q2 25 | 8.8% | — | ||
| Q1 25 | 13.9% | — | ||
| Q4 24 | 8.0% | — | ||
| Q3 24 | -9.6% | — | ||
| Q2 24 | -25.3% | — | ||
| Q1 24 | -4.1% | — | ||
| Q4 23 | -19.7% | — |
| Q3 25 | -2.5% | — | ||
| Q2 25 | 7.8% | — | ||
| Q1 25 | 17.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -11.7% | — | ||
| Q2 24 | -28.0% | — | ||
| Q1 24 | -6.0% | — | ||
| Q4 23 | — | — |
| Q3 25 | $-0.02 | — | ||
| Q2 25 | $0.06 | — | ||
| Q1 25 | $0.16 | — | ||
| Q4 24 | $0.09 | — | ||
| Q3 24 | $-0.09 | — | ||
| Q2 24 | $-0.20 | — | ||
| Q1 24 | $-0.06 | — | ||
| Q4 23 | $-0.15 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
